Increase in plasma levels of adiponectin after administration of anti-tumor necrosis factor agents in patients with rheumatoid arthritis.
Nagashima
Takao
T
Okubo-Fornbacher
Hikaru
H
Aoki
Yoko
Y
Kamata
Yasuyuki
Y
Kimura
Hirotaka
H
Kamimura
Takeshi
T
Nara
Hiroyuki
H
Iwamoto
Masahiro
M
Yoshio
Taku
T
Okazaki
Hitoaki
H
Minota
Seiji
S
D052242:Adiponectin / Q000097:blood*; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000097:blood / Q000188:drug therapy* / Q000208:ethnology; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D000069285:Infliximab; D007564:Japan; D008297:Male; D008875:Middle Aged; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D012044:Regression Analysis; D012720:Severity of Illness Index; D012727:Sex Characteristics; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D052242:Adiponectin; D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068800:Etanercept